Clinical Trials Logo
  1. Home
  2. Diabetes Mellitus, Type 2
  3. NCT00600626
  4. Details
NCT00600626 Clinical Trial

Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes

Diabetes Mellitus, Type 2 Clinical Trial

Official title:
Comparison of Basal Bolus Treatment With Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes Mellitus

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00600626
Other study ID # BIASP-1486
Secondary ID
Status Completed
Phase Phase 3
First received January 14, 2008
Last updated January 5, 2017
Start date January 2004
Est. completion date July 2004

Study information
Verified date January 2017
Source Novo Nordisk A/S
Contact n/a
Is FDA regulated No
Health authority Croatia: Ministry of Health and Social CareFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)Germany: Federal Institute for Drugs and Medical DevicesHong Kong: Department of HealthMalaysia: Ministry of HealthNetherlands: Dutch Health Care InspectoratePoland: The Office for Registration of Medicinal Products, Medical Devices; and Biocides, Central Evidence of Clinical TrialsRomania: State Institute for Drug ControlRussia: Federal Service for Control of Health Care and Social DevelopmentSingapore: Health Sciences AuthoritySpain: Spanish Agency of MedicinesSweden: Medical Products AgencyUnited Kingdom: Medicines and Healthcare Products Regulatory Agency
Study type Interventional

Clinical Trial Summary

This trial is conducted in Europe and Asia. The aim of this trial is to compare basal bolus treatment with insulin aspart and insulin NPH to biphasic insulin aspart treatment on blood glucose control in type 2 diabetes.

Recruitment information / eligibility
Status Completed
Enrollment 394
Est. completion date July 2004
Est. primary completion date July 2004
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Type 2 diabetes

- Currently treated with human insulin or insulin analogues for at least 3 months, with or without combination with OADs

- HbA1c between 8.0-10.5%

- Body mass index (BMI) below 35.0 kg/m2

- Able and willing to perform self-monitoring of blood glucose

Exclusion Criteria:

- Total daily insulin dose of 1.80 IU/kg or more

- Known or suspected allergy to trial product or related products

- Pregnancy, breast-feeding, the intention to become pregnant or judged not to be using adequate contraceptive measures

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• biphasic insulin aspart

• insulin NPH

• insulin aspart

Locations
Country Name City State
Croatia Novo Nordisk Investigational Site Zagreb
France Novo Nordisk Investigational Site Lille
France Novo Nordisk Investigational Site NEVERS cedex
France Novo Nordisk Investigational Site Rennes
France Novo Nordisk Investigational Site Venissieux
Germany Novo Nordisk Investigational Site Bad Heilbrunn
Germany Novo Nordisk Investigational Site Neuss
Germany Novo Nordisk Investigational Site Schaafheim
Germany Novo Nordisk Investigational Site Schwedt
Germany Novo Nordisk Investigational Site St. Ingbert
Germany Novo Nordisk Investigational Site Völklingen
Germany Novo Nordisk Investigational Site Wiesbaden
Germany Novo Nordisk Investigational Site Würzburg
Hong Kong Novo Nordisk Investigational Site Shatin, New Territories
Malaysia Novo Nordisk Investigational Site Cheras
Malaysia Novo Nordisk Investigational Site Kota Bharu, Kelantan
Netherlands Novo Nordisk Investigational Site Beverwijk
Netherlands Novo Nordisk Investigational Site Delft
Netherlands Novo Nordisk Investigational Site Eindhoven
Netherlands Novo Nordisk Investigational Site Rotterdam
Poland Novo Nordisk Investigational Site Lodz
Poland Novo Nordisk Investigational Site Lublin
Poland Novo Nordisk Investigational Site Szczecin
Poland Novo Nordisk Investigational Site Warszawa
Poland Novo Nordisk Investigational Site Zabrze
Romania Novo Nordisk Investigational Site Cluj Napoca Cluj
Romania Novo Nordisk Investigational Site Constanta
Romania Novo Nordisk Investigational Site Iasi
Romania Novo Nordisk Investigational Site Timisoara
Russian Federation Novo Nordisk Investigational Site Moscow
Russian Federation Novo Nordisk Investigational Site Moscow
Russian Federation Novo Nordisk Investigational Site Saint-Petersburg
Russian Federation Novo Nordisk Investigational Site Saint-Petersburg
Singapore Novo Nordisk Investigational Site Singapore
Spain Novo Nordisk Investigational Site Córdoba
Spain Novo Nordisk Investigational Site Madrid
Spain Novo Nordisk Investigational Site Orihuela
Spain Novo Nordisk Investigational Site Sabadell
Spain Novo Nordisk Investigational Site Sevilla
Spain Novo Nordisk Investigational Site Sevilla
Spain Novo Nordisk Investigational Site Valladolid
Sweden Novo Nordisk Investigational Site Falun
Sweden Novo Nordisk Investigational Site Göteborg
Sweden Novo Nordisk Investigational Site Linköping
Sweden Novo Nordisk Investigational Site Lund
Sweden Novo Nordisk Investigational Site Mölndal
Sweden Novo Nordisk Investigational Site Uppsala
United Kingdom Novo Nordisk Investigational Site Bradford
United Kingdom Novo Nordisk Investigational Site Brighton
United Kingdom Novo Nordisk Investigational Site Coventry
United Kingdom Novo Nordisk Investigational Site Edinburgh
United Kingdom Novo Nordisk Investigational Site Glasgow
United Kingdom Novo Nordisk Investigational Site Northampton
United Kingdom Novo Nordisk Investigational Site Plymouth
United Kingdom Novo Nordisk Investigational Site York

Sponsors (1)
Lead Sponsor Collaborator
Novo Nordisk A/S

Countries where clinical trial is conducted

Croatia,  France,  Germany,  Hong Kong,  Malaysia,  Netherlands,  Poland,  Romania,  Russian Federation,  Singapore,  Spain,  Sweden,  United Kingdom, 

References & Publications (1)

Ligthelm RJ, Mouritzen U, Lynggaard H, Landin-Olsson M, Fox C, le Devehat C, Romero E, Liebl A. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel grou — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary HbA1c after 4 months of treatment No
Secondary 8-point blood glucose profile No
Secondary incidence of hypoglycaemic episodes No
Secondary safety profiles No
Secondary changes in body weight and vital signs No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2

External Links